0591-3693 : Paliperidone 3 mg Oral Tablet, Film Coated, Extended Release


NDC0591-3693
Labeler: Actavis Pharma, Inc.
Product Type: Human Prescription Drug
Drug Name:  Paliperidone
Dosage Form: Oral Tablet, Film Coated, Extended Release
Application #: ANDA202645
Rev. Date: 


Appearance:


Markings: WPI;3
Shapes:  Round
Colors:  White
Size (mm): 8
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 0591-3693-10: 1000 TABLET, FILM COATED, EXTENDED RELEASE IN 1 BOTTLE (0591‑3693‑10)
  • 0591-3693-19: 90 TABLET, FILM COATED, EXTENDED RELEASE IN 1 BOTTLE (0591‑3693‑19)
  • 0591-3693-30: 30 TABLET, FILM COATED, EXTENDED RELEASE IN 1 BOTTLE (0591‑3693‑30)

Active Ingredients:

  • Paliperidone

Dosage Strength:

  • 3 mg

Inactive Ingredients:

  • Butylated Hydroxytoluene
  • Cellulose Acetate
  • Silicon Dioxide
  • Fd&c Red No. 40
  • Aluminum Oxide
  • Hydroxypropyl Cellulose (Type H)
  • Hypromelloses
  • Ferrosoferric Oxide
  • Polyethylene Glycols
  • Povidones
  • Propylene Glycol
  • Sodium Chloride
  • Stearic Acid
  • Titanium Dioxide
  • Lactose Monohydrate
  • Triacetin

Pharmaceutical Classes:

  • Atypical Antipsychotic [EPC]

Related Products:

Based on records with the same trade name.
  • 0591-3692 Paliperidone 1.5 mg Oral Tablet, Film Coated, Extended Release by Actavis Pharma, Inc.
  • 0591-3694 Paliperidone 6 mg Oral Tablet, Film Coated, Extended Release by Actavis Pharma, Inc.
  • 0591-3695 Paliperidone 9 mg Oral Tablet, Film Coated, Extended Release by Actavis Pharma, Inc.
  • 0378-3978 Paliperidone 1.5 mg Oral Tablet, Film Coated, Extended Release by Mylan Pharmaceuticals Inc.
  • 0378-3979 Paliperidone 3 mg Oral Tablet, Film Coated, Extended Release by Mylan Pharmaceuticals Inc.
  • 0378-3980 Paliperidone 6 mg Oral Tablet, Film Coated, Extended Release by Mylan Pharmaceuticals Inc.
  • 0378-3981 Paliperidone 9 mg Oral Tablet, Film Coated, Extended Release by Mylan Pharmaceuticals Inc.
  • 0904-6935 Paliperidone 3 mg Oral Tablet, Extended Release by Major Pharmaceuticals
  • 0904-6936 Paliperidone 6 mg Oral Tablet, Extended Release by Major Pharmaceuticals
  • 0904-6937 Paliperidone 9 mg Oral Tablet, Extended Release by Major Pharmaceuticals
  • 10147-0951 Paliperidone 1.5 mg Oral Tablet, Extended Release by Patriot Pharmaceuticals, LLC
  • 10147-0952 Paliperidone 3 mg Oral Tablet, Extended Release by Patriot Pharmaceuticals, LLC
  • 10147-0953 Paliperidone 6 mg Oral Tablet, Extended Release by Patriot Pharmaceuticals, LLC
  • 10147-0954 Paliperidone 9 mg Oral Tablet, Extended Release by Patriot Pharmaceuticals, LLC
  • 16714-866 Paliperidone 1.5 mg Oral Tablet, Extended Release by Northstar Rxllc
  • 16714-867 Paliperidone 3 mg Oral Tablet, Extended Release by Northstar Rxllc
  • 16714-868 Paliperidone 6 mg Oral Tablet, Extended Release by Northstar Rxllc
  • 16714-869 Paliperidone 9 mg Oral Tablet, Extended Release by Northstar Rxllc
  • 27808-222 Paliperidone 1.5 mg Oral Tablet, Extended Release by Tris Pharma Inc
  • 27808-223 Paliperidone 3 mg Oral Tablet, Extended Release by Tris Pharma Inc
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0591-3693 QR Code

< Prev: 0591-3692Next: 0591-3694 >

Related Discussions:

Paliperidone Palmitate
Does IM injection Paliperidone Palmitate (Invega Sustenna) lose potency or become unsafe if it has been stored in far ab... 2 replies
Paliperidone withdrawal. Will the receptors be unblocked?
I've been taking the Xeplion (Paliperidone) injection for about a year now. This drug blocks the serotonin and dopam...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.